Inicio
Markets
Charts & Ideas
Algo
Noticias
Store
Corredores
Descargar
Calendario económico
Señales Comerciales
WebTerminal
Pulse
/
para buscar: @user, $symbol, ...
Buscar
Entrada
Crear una cuenta
Español
English
Русский
中文
Português
日本語
Deutsch
한국어
Français
Italiano
Türkçe
GLMD
#4055
Galmed Pharmaceuticals Ltd.
0.6
1
-7.58%
Sector:
Básica:
Profit Currency:
Rango diario
Rango anual
Cambio diario
-7.58%
Monthly Change
-28.24%
6 month change
-56.74%
Cambio anual
-72.27%
Cierres anteriores
0.6
6
Open
0.6
1
Bid
Ask
Low
0.6
1
High
0.6
1
Volumen
2
Markets
Acciones
Atención Sanitaria
GLMD
Open full chart
Financials
Overview
Statement
Statistics
Dividends
Quarterly
Annual
Value
Q4, 24
TTM
Key stats
Total common shares outstanding
1.65 M
2.35 M
Valuation ratios
Enterprise value
577.63 K
—
Price to earnings ratio
0.39
—
Price to sales ratio
—
—
Price to cash flow ratio
0.5
—
Price to book ratio
0.18
—
Enterprise value to EBITDA ratio
—
—
Profitability ratios
Return on assets %
-0.19
-0.85
Return on equity %
-0.21
-1.02
Return on invested capital %
—
—
Gross margin %
—
—
Operating margin %
—
—
EBITDA margin %
—
—
Net margin %
—
—
Liquidity ratios
Quick ratio
—
—
Current ratio
7.42
23.13
Inventory turnover
—
—
Asset turnover
—
—
Solvency ratios
Debt to assets ratio
—
—
Debt to equity ratio
—
—
Long term debt to total assets ratio
0.05
0.16
Long term debt to total equity ratio
0.05
0.19
Per share metrics
Operating cash flow per share
-3.71
-105.21
EBIT per share
—
—
EBITDA per share
—
—
Total debt per share
—
—
Cash per share
12.78
411.18
Net current asset value per share
17.32
443.93
Tangible book value per share
17.54
396.94
Working capital per share
14.99
364.51
Book value per share
17.54
396.94
Noticias
Galmed Pharmaceuticals convoca reunión especial de accionistas para el 4 de marzo
Galmed Pharmaceuticals convoca junta extraordinaria de accionistas para el 4 de marzo
Galmed Pharmaceuticals schedules special shareholder meeting for March 4
Galmed Pharmaceuticals recibe aviso de precio un mínimo de oferta de Nasdaq
Galmed Pharmaceuticals recibe aviso de precio un mínimo de oferta de Nasdaq
Galmed Pharmaceuticals receives Nasdaq minimum bid price notice
Galmed presentará datos sobre potencial de Aramchol en cáncer hepático
Galmed to present data on Aramchol’s potential in liver cancer
Acciones de Galmed suben tras patente para terapia combinada contra MASH
Las acciones de Galmed suben tras la concesión de patente para terapia combinada contra el MASH
Galmed stock rises after patent grant for MASH combo therapy
Galmed recibe patente en Corea del Sur para terapia combinada